Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

PANCRELIPASE
Trade names: Cotazym (Organon); Creon (Solvay); Ilozyme;
Ku-Zyme; Lipram; Pancoate; Pancrease (Ortho-McNeil);
Panokase (Breckenridge); Protilase; Ultrase (Axcan); Viokase
(Axcan); Zymase
Indications: Pancreatic insufficiency, Steatorrhea
Category: Enzyme
Half-life: N/A
Clinically important, potentially hazardous interactions
with: None
Skin
Dermatitis
Peripheral edema
Rash (sic) (rare)
Mucosal
Oral mucosal irritation
Other
Abdominal pain
Reactions
PANCURONIUM
Trade names: Alpax; Bromurex; Curon-B; Panconium; Panslan
Indications: Anesthesia adjunct, neuromuscular blockade,
muscle relaxant
Category: Non-depolarizing neuromuscular blocker
Half-life: 89–161 minutes
Clinically important, potentially hazardous interactions
with: aminoglycosides, cortisone, cyclopropane, enflurane,
gentamicin, halothane, hydrocortisone, isoflurane, kanamycin,
methoxyflurane, neomycin, piperacillin, prednisolone,
prednisone, streptomycin, tobramycin
Reactions
Skin
Burning
Edema
Erythema
(1989): Patriarca G+, Br J Anaesth 62(2), 210
Pruritus
Rash (sic)
Mucosal
Sialorrhea
Other
Anaphylactoid reactions/Anaphylaxis
(1998): Sanchez-Guerrero IM+, Eur J Anaesthesiol 15(5), 613
(1990): Moneret-Vautrin DA+, Br J Anaesth 64(6), 743
(1989): Patriarca G+, Br J Anaesth 62(2), 210
(1986): Bonnet MC+, Cah Anesthesiol 34(3), 253
(1985): Conil C+, Ann Fr Anesth Reanim 4(2), 241
(1985): Galletly DC+, Anaesthesia 40(4), 329
(1985): Moneret-Vautrin DA+, Anesth Analg 64(9), 944
(1984): Mishima S+, Anesth Analg 63(9), 865
(1984): Pappagallo S+, Minerva Anestesiol 50(9), 481
Hypersensitivity
(1983): Nagao H+, Br J Anaesth 55(3), 253
Myalgia/Myositis/Myopathy/Myotoxicity
(1994): Giostra E+, Chest 106(1), 210
(1993): De Smet, Rev Neurol 149(10), 573
(1993): Miyoshi T+, Rinsho Shinkeigaku 33(6), 620
Rhabdomyolysis
(1993): Clavelou P+, AnnFrAnesthReanim12(3), 326
PANITUMUMAB
Synonym: ABX-EGF
Trade name: Vectibix (Amgen)
Indications: Metastatic colorectal carcinoma (to reduce
progression of)
Category: Monoclonal antibody
Half-life: ~7.5 days
Clinically important, potentially hazardous interactions
with: N/A
Reactions
PANITUMUMAB 415
Skin
Acne (57%)
(2005): Segaert S+, Ann Oncol 16(9), 1425
(2005): Segaert S+, J Dtsch Dermatol Ges 3(8), 599
Eczema
(2005): Segaert S+, Ann Oncol 16(9), 1425
(2005): Segaert S+, J Dtsch Dermatol 3(8), 599
Erythema (65%)
Exfoliative dermatitis (25%)
Fissures (20%)
(2005): Segaert S+, Ann Oncol 16(9), 1425
Peripheral edema (12%)
Pigmentation
(2005): Segaert S+, Ann Oncol 16(9), 1425
Pruritus (57%)
Rash (sic) (22%)
(2006): Gibson TB+, Clin Colorectal Cancer 6(1), 29
(2006): Saif MW+, Clin Colorectal Cancer 6(2), 118 (90%)
Telangiectasia
(2005): Segaert S+, Ann Oncol 16(9), 1425
Xerosis (10%)
(2005): Segaert S+, Ann Oncol 16(9), 1425
(2005): Segaert S+, J Dtsch Dermatol 3(8), 599
Mucosal
Oral mucositis (6%)
Stomatitis (7%)
Hair
Hair – changes (sic)
(2005): Segaert S+, Ann Oncol 16(9), 1425
(2005): Segaert S+, J Dtsch Dermatol 3(8), 599
Nails
Nails – changes
(2005): Segaert S+, J Dtsch Dermatol 3(8), 599
Nails – paronychia (25%)
(2005): Segaert S+, Ann Oncol 16(9), 1425
Nails – pyogenic granulomas
(2005): Segaert S+, Ann Oncol 16(9), 1425
Eyes
Conjunctivitis (4%)
Eyelashes – hypertrichosis
Eyelid irritation (1%)
Lacrimation (2%)
Toxicity (sic) (9%)